Dimitri Kereselidze
Overview
Explore the profile of Dimitri Kereselidze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chevaleyre C, Zimmermann L, Specklin S, Kereselidze D, Bouleau A, Dubois S, et al.
J Nucl Med
. 2025 Feb;
PMID: 39978814
The development of resistance significantly hampers the efficacy of immunotherapies in cancer treatment. The combination of JQ1, a BRD4 protein inhibitor, and anti-programmed death ligand 1 (PD-L1) immunotherapies has a...
2.
Martin-Aubert S, Avrillon K, Tournier N, Bordat A, Tran V, Ibrahim N, et al.
J Control Release
. 2024 Dec;
378:803-813.
PMID: 39719212
Mertansine (DM1), a potent tumor-killing maytansinoid, requires conjugation to antibodies or incorporation into nanocarriers due to its high toxicity. However, these carriers often result in undesirable biodistribution, leading to rapid...
3.
Riberaud M, Porret E, Pruvost A, Theodoro F, Nguyen A, Specklin S, et al.
Chem Sci
. 2024 Oct;
PMID: 39464609
The accurate quantification of biomarkers is paramount in modern medicine, particularly in cancer where precise diagnosis is imperative for targeted therapy selection. In this paper we described a multiplexed analysis...
4.
Hautiere M, Vivier D, Dorval P, Pineau D, Kereselidze D, Denis C, et al.
Theranostics
. 2024 Oct;
14(16):6268-6280.
PMID: 39431005
Glioblastoma (GBM) poses significant challenges regarding complete tumor removal due to its heterogeneity and invasiveness, emphasizing the need for effective therapeutic options. In the last two decades, fluorescence-guided surgery (FGS),...
5.
Meyblum L, Chevaleyre C, Susini S, Jego B, Deschamps F, Kereselidze D, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 37949616
Background: Despite the promising efficacy of immune checkpoint blockers (ICB), tumor resistance and immune-related adverse events hinder their success in cancer treatment. To address these challenges, intratumoral delivery of immunotherapies...
6.
Chevaleyre C, Novell A, Tournier N, Dauba A, Dubois S, Kereselidze D, et al.
Theranostics
. 2023 Nov;
13(15):5584-5596.
PMID: 37908736
The passage of antibodies through the blood-brain barrier (BBB) and the blood-tumoral barrier (BTB) is determinant not only to increase the immune checkpoint inhibitors efficacy but also to monitor prognostic...
7.
Hautiere M, Vivier D, Pineau D, Denis C, Kereselidze D, Herbet A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jun;
50(11):3192-3201.
PMID: 37280303
Background: The resistance of glioblastoma stem cells (GSCs) to treatment is one of the causes of glioblastoma (GBM) recurrence. Endothelin A receptor (ET) overexpression in GSCs constitutes an attractive biomarker...
8.
Porret E, Kereselidze D, Dauba A, Schweitzer-Chaput A, Jegot B, Selingue E, et al.
Eur J Pharm Biopharm
. 2022 Dec;
182:141-151.
PMID: 36529256
Introduction: Glioblastoma (GBM) is the most common and deadly form of primary brain tumor. Between 30 % and 60 % of GBM are characterized by overexpression of the Epidermal Growth...
9.
Chevaleyre C, Kereselidze D, Caille F, Tournier N, Olaciregui N, Winkeler A, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293329
Diffuse intrinsic pontine gliomas (DIPG), the first cause of cerebral pediatric cancer death, will greatly benefit from specific and non-invasive biomarkers for patient follow-up and monitoring of drug efficacy. Since...
10.
Yang X, Tran V, Remita H, Savina F, Denis C, Kereselidze D, et al.
Nanomedicine
. 2022 Sep;
46:102603.
PMID: 36116695
Personalized medicine approach in radiotherapy requires the delivery of precise dose to the tumor. The concept is to increase the effectiveness of radiotherapy while sparing the surrounding heathy tissue. This...